Sqz Biotechnologies Company Stock News

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernar

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regene

SQZ Biotechnologies Company (NYSE: SQZ) has announced preclinical results from its Tolerizing Antigen Carrier (TAC) program, showing potential for application in various autoimmune diseases. Data w

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, is presenting preclinical results

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results fr

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be pa

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, man

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported financial results for the

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participat

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participat

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results a

SQZ Biotechnologies is a cell therapy manufacturing company developing its own pipeline of medicines. The investment thesis is centered around a large market opportunity to treat HPV+ solid tumors and

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief exec

The cell-squeezing specialist priced a new stock issue.

SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.